1 of 1
Story summary
- Researchers from Stanford University, Emory University, the University of North Carolina at Chapel Hill, Utah State University, and the University of Arizona developed a nasal spray vaccine named GLA-3M-052-LS+OVA.
- In mice, it produced immunity lasting at least three months against SARS-CoV-2 and other viruses.
- It stimulates the lungs' immune response by activating cells.
- If human trials succeed, the vaccine could replace annual shots within five to seven years.
